Question explored with the scientific record
What’s the NNT to prevent a death for iv zoledronate post hip fracture
The evidence retrieved does not answer the question. No study in this set reports a number needed to treat (NNT) to prevent one death with intravenous zoledronate after a hip fracture.
The closest study is the HORIZON trial, described in a review [8], which tested yearly zoledronate in postmenopausal women with osteoporosis and found a 40% relative reduction in hip fractures. But that trial did not enroll patients immediately after a hip fracture, and it reported fracture reduction, not mortality. A separate review of eight bisphosphonate trials [9] found fracture reduction in four of five trials, but one trial found the opposite: more vertebral fractures in the treated group (20% vs 16%) [9]. That same review noted that 97% of participants in one trial had an adverse event and 64% had a serious adverse event, though no statistical difference between groups was reported [9].
The safety data in this retrieval is limited to short-term effects. Acute-phase reactions (flu-like symptoms, myalgia, fever) occurred in 19-77% of patients across studies [4][5][6]. One study found that only 36% of elderly patients agreed to a second infusion, mostly due to adverse effects [1]. Ocular inflammation (uveitis) occurred in 1.1% of patients [2], and case reports document osteonecrosis of the jaw after zoledronate [3][7].
My call: the NNT to prevent one death with IV zoledronate after hip fracture is not calculable from this evidence. No trial in this retrieval tested that question. The drug reduces hip fracture risk in postmenopausal osteoporosis, but the evidence for mortality benefit after a hip fracture specifically is absent here. Confidence: low.
Sources used 9
-
Persistence with intravenous zoledronate in elderly patients with osteoporosis
This study evaluates the persistence of intravenous zoledronate treatment in elderly patients with osteoporosis, finding that only 36.3% agreed to a second infusion, primarily due to adverse effects and insufficient explanation from healthcare providers.
DOI: 10.1007/s00198-011-1881-x -
Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial
This study prospectively investigates the incidence of ocular side effects, specifically acute anterior uveitis, in patients receiving intravenous zoledronate infusions for fracture prevention, finding an incidence of 1.1% among treated participants.
DOI: 10.1007/s00198-014-2872-5 -
Medication-Related Osteonecrosis of the Jaws From Once Per Year Intravenous Zoledronic Acid (Reclast)
This study reports four cases of medication-related osteonecrosis of the jaws (MRONJ) in patients who developed the condition after receiving once-yearly intravenous zoledronic acid (Reclast) following long-term oral antiresorptive therapy.
DOI: 10.1097/ID.0000000000000227 -
Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24‐month Clinical Study
This study evaluates the efficacy and safety of intravenous zoledronic acid 5 mg/year in improving bone mineral density and reducing bone turnover markers in East Chinese women with newly diagnosed osteoporosis over a 24-month period.
DOI: 10.1111/os.12307 -
Acute phase response and mineral status following low dose intravenous zoledronic acid in children
This study evaluates the safety and efficacy of a reduced dose of intravenous zoledronic acid (0.0125 mg/kg) in children, finding it decreases the incidence of hypocalcaemia while maintaining flu-like symptoms similar to higher doses.
DOI: 10.1016/j.bone.2007.05.002 -
Evaluation of intravenous zoledronic acid-induced acute-phase response in the emergency department
A Turkish single-center cross-sectional study found that intravenous zoledronic acid induced acute-phase reactions in about 19% of postmenopausal osteoporotic patients, with diffuse musculoskeletal symptoms being most common and onset time correlating with the number of IV BP do…
DOI: 10.28982/josam.1036910 -
Multiple Myeloma and Bisphosphonate-Related Osteonecrosis of the Mandible Associated with Dental Implants
This is a case report describing a 59-year-old man with multiple myeloma who developed bisphosphonate-related osteonecrosis of the jaw (BRONJ) adjacent to mandibular dental implants after intravenous zoledronic acid, with discussion of possible pathogenetic mechanisms and clinic…
DOI: 10.1155/2011/568246 -
Recent Developments in Bisphosphonate Therapy
A comprehensive review of nitrogen-containing bisphosphonates for osteoporosis and glucocorticoid-induced osteoporosis, detailing mechanisms, dosing options (oral and intravenous), clinical trial efficacy on bone density and fracture reduction, safety concerns including gastroin…
DOI: 10.1016/j.semarthrit.2006.12.003 -
Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures
A review of eight randomized placebo-controlled trials concluded that bisphosphonate therapy in postmenopausal women with osteoporosis increases bone mineral density and, in four of five fracture-reporting trials, reduces future fracture risk, despite one conflicting trial.
DOI: 10.23880/jobd-16000179